Novartis was created in 1996 through a merger of Ciba-Geigy Sandoz. Novartis and its predecessor companies trace roots back more than 250 years, with a rich history of developing innovative products. Novartis operates businesses with global scale and strong customer ties, focusing on innovative patented medicines, generics and eye care devices. We use science-based innovation to address some of society's most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
Our global portfolio of innovative patented medicines includes more than 50 key marketed products, many of which are among the leaders in their therapeutic areas.We invest in the development of new technologies that improve patient adherence and help predict individual response to treatment.Our goal is to optimize patient outcomes by delivering targeted treatments.
By beginning to genetically identify patients who will respond positively to particular therapies, we are starting to tackle two of the greatest challenges in developing drugs: identifying a disease area with a critical, unmet need and assigning studies to test a clinical hypothesis.
Teams across Novartis work together to develop customized therapies for patients.